Literature DB >> 6228294

Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.

R G Pretorius, N F Hacker, J S Berek, L C Ford, J D Hoeschele, T A Butler, L D Lagasse.   

Abstract

Four patients with small residual ovarian carcinoma following treatment with cisplatin, doxorubicin, and cyclophosphamide have subsequently received 57 courses of ip cisplatin. Cisplatin (120-270 mg in 2 L of Ringer's lactate) was administered via Tenckhoff catheter, with a dwell time of 15-20 mins. Courses were given weekly for 12 weeks, with response documented by laparoscopy or laparotomy prior to and following the trial. With a dwell time of 20 mins, 75% +/- 5% (mean +/- SD) of platinum was recovered. With 120 mg of cisplatin and a dwell time of 20 mins, total plasma platinum peaked at 1.23 +/- 0.42 microgram/ml and by 8 hrs decreased to 0.67 +/- 0.12 microgram/ml. Filterable (non-protein-bound) platinum peaked at 0.73 +/- 0.21 microgram/ml and by 8 hrs fell to 0.03 microgram/ml. Excretion rate paralleled the filterable plasma curve, peaking at 40 mins; 30% +/- 7% of absorbed drug was recovered in urine within 24 hrs. Renal clearance of filterable platinum was 106 +/- 20 ml/min. Creatinine clearance was 76 +/- 7 ml/min. Three responses, one complete and two partial, were noted. Zero to two episodes of vomiting occurred in each course. One patient had a creatinine clearance decrease to 40 ml/min, one had two episodes of thrombocytopenia, and one had mild abdominal pain with a cisplatin dose of greater than or equal to 210 mg. No neurotoxicity, catheter infection, or peritonitis was encountered.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228294

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  14 in total

1.  Intraperitoneal chemotherapy for epithelial ovarian cancer - single center experience.

Authors:  Rajshekhar C Jaka; S P Somashekhar; Shabber S Zaveri; Zahoor Ahmed; K R Ashwin
Journal:  Indian J Surg Oncol       Date:  2012-07-04

2.  Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.

Authors:  F Figoli; M L Zanette; U Tirelli; R Sorio; C Lestuzzi; R Urso; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Practical considerations in ovarian cancer chemotherapy.

Authors:  Mihaela Cristea; Ernest Han; Lennie Salmon; Robert J Morgan
Journal:  Ther Adv Med Oncol       Date:  2010-05       Impact factor: 8.168

4.  Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).

Authors:  P A Reece; I Stafford; J Russell; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.

Authors:  P Canal; R Bugat; C Michel; H Roche; G Soula; P F Combes
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.

Authors:  Maurie Markman; Jerome Belinson
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-21       Impact factor: 4.553

Review 7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time?

Authors:  Paul L Feingold; Mei Li M Kwong; Arvind Sabesan; Rebecca Sorber; Udo Rudloff
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 8.  Intracavitary chemotherapy for malignant disease confined to body cavities.

Authors:  M Markman
Journal:  West J Med       Date:  1985-03

9.  [Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].

Authors:  H Rückle; G Ehninger; F Jakob; K Wilms
Journal:  Klin Wochenschr       Date:  1986-05-15

10.  Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.

Authors:  Emmanuel Guardiola; Delphine Delroeux; Bruno Heyd; Marielle Combe; Veronique Lorgis; Martin Demarchi; Ulrich Stein; Bernard Royer; Bruno Chauffert; Xavier Pivot
Journal:  World J Surg Oncol       Date:  2009-02-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.